Contact Us Home Capabilities Our Team In The Media LifeSci Partners Copyright 2020 LifeSci Communications Blog

LifeSci Communications Clients in the Media

Applying A Synthetic Approach To The Development Of A New Generation Of Antibiotics

Australian company Recce Pharmaceuticals (ASX: RCE) is advancing a synthetic polymer antibiotic designed with optimum properties that exhibits high potency against a broad range of…

READ MORE

Epigenetic Regulation To Treat Acute Organ Injury And Chronic Liver Diseases

DURECT Corporation is advancing an epigenetic regulator program aimed at developing products to treat acute AH and nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty…

READ MORE

Jeff Wolf: Congress and the administration: Seniors and certain minority groups need a ‘super-vaccine’

The critical difference is that older patients and those who are immune-compromised tend to lack a robust T-cell response, which Heat Biologics believes is important…

READ MORE

Assembling a Pipeline for Rare GI Disorders

9 Meters Biopharma is focused on rare gastrointestinal conditions. It is advancing an experimental therapy for short bowel syndrome. We spoke to John Temperato, president…

Listen here

Aligos Therapeutics — The Next Step Of Lawrence Blatt’s Entrepreneurial Expedition

Not long ago, someone asked Lawrence Blatt, Ph.D., the probability that one of his company’s drugs would be successful. “I don’t want to think about…

READ MORE

Chiasma secures FDA approval for acromegaly pill Mycapssa years after near-catastrophic rejection

Chiasma’s Mycapssa (octreotide) has become the first FDA-approved oral therapy to treat acromegaly, a rare disorder in which overproduction of human growth hormone leads to…

READ MORE

Treating Huntington’s Disease by Addressing Neuroinflammation

Huntington’s disease is a rare and fatal neurodegenerative condition that is without any disease-modifying therapies today. Vaccinex is developing an experimental therapy designed to treat…

Listen here

Former Sen. Harry Reid Says He’s in ‘Complete Remission’ After Pancreatic Cancer Treatment

Dr. Soon-Shiong tells PEOPLE he’s working to create a more universal cancer treatment by rethinking how we use radiation to target cancer cells – and…

READ MORE

Will We Ever Find a Cure for Dementia?

This precise approach “makes it possible to make drugs that only act on the cell type you care about,” reducing the unwanted side effects that…

READ MORE

New emergency COVID-19 drug in testing phase excites South Florida doctors

Dr. Jonathan Javitt, the CEO of NeuroRx, said, “We’re talking to people who have critical COVID-19, with respiratory failure. That is people whose lungs have…

READ MORE

Winston-Salem woman raises awareness about Huntington’s disease

“It’s a chronic neurodegenerative process. Chronic just means it goes on very slowly over a long period of time,” said Friedlander, of NeuBase Therapeutics. Holder’s…

READ MORE

Yeliva see anything: Redhill calls out opaganib’s promise in COVID-19

Redhill Biopharma Ltd.’s chief operating officer, Gilead Raday, told BioWorld that the firm will build on positive results in severe COVID-19 patients with oral opaganib, a first-in-class sphingosine…

READ MORE

9 Meters Beats Corporate Competitors to Phase III Celiac Trials

9 Meters Biopharma’s program for celiac disease is among the most clinically advanced programs in development. With phase III trials underway and Fast Track designation…

READ MORE

David Gilham on Single Vector Multiplexed shRNA Maintenance

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple…

View clip

Mechanistic Action: Genesis Of A Biologics Pipeline?

It’s early days for Cue Biopharma’s CUE-101, the lead candidate in its IL-2-based CUE-100 Series. In pre-clinical studies, CUE-101 has demonstrated selective binding and preferential…

READ MORE

No-one left behind: ensuring Covid-19 vaccines are effective in at-risk groups

Despite being most at risk from Covid-19, older people and those with compromised immune systems are unlikely to reap much benefit from Covid-19 vaccines, which…

READ MORE

Episode 20-25 Why We Drive – And Why We are Going to Miss It

Moira speaks with Yochi Slonim, CEO of Anima Biotech, talks about the path from your DNA to producing proteins, and the potential for new drugs.

Listen here

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal…

READ MORE

Sisters Network spreads awareness of new TNBC treatment

When Karen Jackson founded Sisters Network INC. in 1994, a national African American breast cancer survivorship organization, she was optimistic to the point of wearing…

READ MORE

Tackling a “Genius Virus”: Dr Patrick Soon-Shiong

Dr. Patrick Soon-Shiong is a physician, surgeon, researcher, philanthropist, and owner of the LA Times. From 1997–2010, he served as Founder, Chairman and CEO of American Pharmaceutical Partners…

READ MORE

A New Cost Paradigm For CAR Cell Therapies?

Efficacy, safety, and convenience are hard-to-achieve attributes of cancer therapies, despite the best marketing engines in biopharma. Acepodia—a clinical-stage biotech focused on developing novel, targeted, allogeneic-cell…

READ MORE

‘I feel good. I’m alive’: Two years after diagnosis, Harry Reid says he’s cancer free

Harry M. Reid has a message for these incredibly bleak times: Keep fighting. Last summer the former Senate majority leader hid from the obvious fact…

READ MORE

Doctor who treated former Nevada Sen. Harry Reid’s cancer now focusing on coronavirus

The scientist whose unorthodox approach helped former Senate Majority Leader Harry Reid beat pancreatic cancer is turning his attention toward fighting coronavirus. Dr. Patrick Soon-Shiong, who said his company ImmunityBio is working…

READ MORE

How an Israeli web service, a bong-like insulin device and a Bay Area deal led this Peninsula biotech to attack a childhood disease

With deep roots in diabetes, this small company is pushing forward with a trial against a rare diosease known as congenital hyperinsulinism.

READ MORE

Woman of the Week Podcast

Dr. Rebecca Kusko, Chief Strategy Officer at Immuneering Corp., has carved out a purposeful, yet unorthodox, path to the C-suite as well as serving as…

Listen here

Genetic Manipulation of T-cells Driving Next Generation Immuno-Oncology with Dr. Laurence Cooper Ziopharm

Dr. Laurence Cooper, CEO, Ziopharm Oncology points to earlier work in immunotherapy to explain the advances in cancer treatment that revolve around the genetic engineering of…

Listen here

A drug for COVID-19 breathing problems, tested in Minnesota, shows promise

Mark Revord will never know for sure whether an experimental drug, known at the time as CM4620-IE, saved him from having a breathing tube inserted…

READ MORE

Why Companies Are Making Billions of COVID-19 Vaccine Doses That May Not Work

Fauci is “cautiously optimistic” that with multiple vaccine candidates being developed using different platforms, we’ll eventually have an effective COVID-19 vaccine. However, Dr. Patrick Soon-Shiong, CEO…

READ MORE

Seeing the light – visualising protein translation in real time

Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who discusses a novel technology that…

READ MORE

Interim analysis indicates Auxora™ is effective in severe COVID-19 pneumonia patients

CalciMedica Inc. revealed that, in combination with low-flow oxygen therapy, Auxora reduced the proportion of patients put on ventilators by over 50 percent compared to the…

READ MORE

Immuno-oncology Enterprises Entering COVID

The era of COVID-19 has brought on some exciting developments with the types of biopharmaceutical enterprises that are developing therapies and vaccines to treat the…

READ MORE

Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study

Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no…

READ MORE

Pepinemab Clinical Trial Ongoing; Top-line Results Coming Later this Year

Vaccinex’s Phase 2 SIGNAL study, evaluating the investigational antibody pepinemab (VX15/2503) in Huntington’s disease patients with late prodromal and early disease, is ongoing and has tested pepinemab in…

READ MORE

Data recommend RECCE 327

Australian drug developer Recce Pharmaceuticals has announced new data showing significant in-vivo antibacterial activity in mice treated with its lead compound RECCE 327 against Neisseria gonorrhoeae, the second most common…

READ MORE

Announcing the 2020 Bulldog PR Award Winners—congrats, top dogs!

Best Use of Social Media – Bronze: Using the Power of Social Media to Engage with Target Audiences in a Crowded Disease Space by LifeSci Communications Best Use…

READ MORE

Episode 5: Finding Funding In Volatile Times With Ben Zeskind

Ben Zeskind launched his biotech, Immuneering, in the throes of the Great Recession. The company earned a $20 million series A round to fund the…

Listen here

Pharmafocus June 2020

“Seeing a group of people become a team and achieving more than they thought was possible inspires me” – Anne Whitaker, CEO, Aerami Therapeutics

READ MORE

Operation Warp Speed selects billionaire scientist’s COVID-19 vaccine for monkey tests

The race for a COVID-19 vaccine has a dark horse entrant. Billionaire scientist and businessman Patrick Soon-Shiong announced in a 27 May investor call and…

READ MORE

After Final Medicare LCD from Palmetto GBA, OncoCyte Pursues Private Coverage for NSCLC Stratification Test

Molecular diagnostics developer OncoCyte said it will step up its pursuit of coverage by private insurers for its DetermaRx™ non-small cell lung cancer (NSCLC) test,…

READ MORE

ASCO: Ziopharm’s IL-12 gene therapy boosts survival in hard-to-treat brain cancer

Radiation, chemotherapy and surgery don’t cut it against glioblastoma, an aggressive type of brain cancer that often recurs with a vengeance. Ziopharm is working on…

READ MORE

Covid-19 vaccine being produced in West Lothian plant

Work is already underway at Valneva’s plant in Livingston on the unique Covid-19 inactivated vaccine.

READ MORE

Developing next-generation CAR T cell therapies to bridge the gap in personalised medicine

Filippo Petti, Chief Executive Officer at Celyad, delves into the disruptive potential of CAR T therapies in treating cancer, and explores the challenges that have…

READ MORE

A Conversation on Vaccine Hesitancy in COVID-19 Times

Significant efforts are underway to develop a vaccine against SARS-CoV-2, the virus that has caused the COVID-19 global pandemic. A critical factor of consideration is the potential impact…

READ MORE

Why Listening to Patient Organizations is Key in Drug Development

As the biotech industry flourishes and therapies become more targeted and personalized, the need for drug developers to interact with patients is increasing as well.…

READ MORE

Antifungal and Antiviral Conjugates Platforms Fighting Infectious Diseases with Jeff Stein Cidara Therapeutics

Jeff Stein, President and CEO, Cidara Therapeutics talks about  their antifungal platform rezafungin now in Phase 3 clinical development to address the needs of the…

Listen here

How Can Early-Stage Medical Device Companies Survive Market Turmoil?

David Hochman, founder and CEO of Orchestra BioMed, shares how the company’s risk-reward sharing business model has helped it stay afloat during the coronavirus pandemic.

READ MORE

ImmunityBio’s Promising Preclinical HIV Drug is Moving into Phase I Trials

Human immunodeficiency virus (HIV) management has come a long way, now making it possible for people with HIV to live longer, healthier lives. Antiretroviral therapy…

READ MORE

Vaccinex’s Cancer Research May Lead to Effective Treatment for Deadly Huntington’s Disease

Huntington’s disease (HD), also known as Huntington’s chorea, is an inherited genetic disorder that kills brain cells. The Huntington Disease Society of America describes the disease as “a fatal genetic…

READ MORE

Fountain fires up aging drugs platform with new $6M financing

Fountain Therapeutics Inc., a California company working to create treatments for age-related diseases, said Khosla Ventures has led a $6 million series A-1 financing of…

READ MORE

Will Covid-19 Change the Face of Vaccine Development?

“Significant investment, in both time and money, is needed to advance a vaccine candidate to market,” Thomas Lingelbach, CEO of French vaccine developer Valneva, told me. “In…

READ MORE

How to launch a drug in a pandemic with Immunomedics

During the ongoing Covid-19 pandemic, the FDA has continued in its normal role of approving safe and effective drugs. But how do pharma companies go…

READ MORE

Saturday Special- Colin speaks with Dr. Patrick Soon-Shiong

Colin talks with Dr. Patrick Soon-Shiong who is not only a Doctor helping to fight Covid-19 but also owns the LA Times and is a…

Listen here

Motus GI receives patent for Pure-Vu’s sensing, suction control

Motus GI has receiving a new United States Patent for the sensing technology and suction control on its Pure-Vu System, a device that fits onto…

READ MORE

Bill Gates among investors as Cambridge Science Park-based Cerevance raises $45m to fight brain diseases

Bill Gates and GV have joined in a $45million Series B funding round for Cerevance, the pharmaceutical company with a Cambridge Science Park base. The…

READ MORE

Ansun Seeks to Reprise Chinese Covid-19 Drug Trial Results in U.S.

When the coronavirus pandemic shook up Ansun Biopharma Inc.’s clinical-trial plans, company leaders knew they had to change course. San Diego-based Ansun, which has raised…

READ MORE

Funding talks for Scottish production of potential Covid-19 vaccine

A specialty vaccine company is seeking grant funding to ramp up production of a potential inoculation against Covid-19 from its Scottish laboratory. French-headquartered Valneva is…

READ MORE

VIVEX to Expand Footprint in Florida to Support Regenerative Medicine Technologies

Back injuries are no joke. Even minor muscle strains can inhibit activities for some time. More serious injuries create greater challenges and often require more…

READ MORE

Arshad Khanani, MD: ADVM-022 Insights from OPTIC Trial Cohorts 1-3

After presenting initial data from Cohorts 1 and 2 of the phase 1 OPTIC trial in 2019, Cohort 3 results announced by Adverum Biotechnologies are…

READ MORE

Ansun Biopharma Takes Aim at COVID-19 with Experimental Influenza Treatment

San Diego-based Ansun Biopharma used its influenza research data to dive into attempts to develop a treatment for COVID-19 using an investigational nebulized enzyme asset…

READ MORE

Study: ANG-3777 effective in reducing delayed kidney function in transplant patients

Use of the hepatocyte growth factor mimetic ANG-3777 showed long-term improvement in kidney function in patients who underwent transplantation but had signs of possible kidney…

READ MORE

Motus GI gains new patent for flagship colonoscopy prep system — 3 quick points

Motus GI secured a U.S. patent for its Pure-Vu System’s sensing technology and suction control features. Three quick points: 1. Motus GI’s flagship Pure-Vu System can…

READ MORE

Katie Jackson, President and CEO of Help 4 HD International Inc. speaks with Maurice Zauderer, Ph.D., CEO of Vaccinex

Maurice Zauderer, Ph.D. has served as Vaccinex’s President and Chief Executive Officer and a member of the board of directors since the company’s inception in…

Listen here

Coordinates of COVID-19 Press Aligos Therapeutics To Pivot On Multiple Fronts

Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, a San Francisco-based biotech discovering and developing curative treatments for hepatologic diseases and viral infections, will…

READ MORE

2 Bay Area companies ramp up in quests for one-shot-and-done gene therapies

BioMarin (NASDAQ: BMRN) of San Rafael paired with one-year-old Swiss company DiNAQOR AG to develop gene therapies to treat rare genetic heart diseases and Adverum…

READ MORE

Intravenous immunoglobulins, hyperimmunes and pandemic viruses

David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.…

READ MORE

Convalescent serum lines up as first-choice treatment for coronavirus

A group of US academic researchers has sparked a nationwide effort to encourage people who have recovered from COVID-19 to donate plasma, which will be used to…

READ MORE

Reddit Email Flush with $22M, newly merged 9 Meters Biopharma launches in Raleigh with focus on GI diseases

Introducing 9 Meters Biopharma, the new company birthed from the merger of Raleigh-based Innovate Biopharmaceuticals, a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune…

READ MORE

It Will Probably Take Longer Than 12 to 18 Months to Get a Vaccine

Producing so many doses will require creating new facilities or commandeering those used for other vaccines. Critics of RNA and DNA vaccines point to the…

READ MORE

5 Biopharma Execs Reveal Corporate Culture Best Practices

It’s early, not even 7 a.m., in fact, and the above statement is prefaced with an apology for interrupting the free-flowing dialogue taking place between…

READ MORE

FDA clears Synaptive’s smaller, point-of-care MRI scanner

Synaptive Medical received an FDA clearance for its slightly miniaturized and more-manageable MRI system, the second such device to receive the agency’s green light in…

READ MORE

Developing respiratory therapeutics for prophylaxis and treatment

With the scale of the COVID-19 pandemic still growing, many pharmaceutical companies are adapting their current R&D programmes to develop therapeutics or vaccines to help…

READ MORE

Henry Adewoye, MD, on the Phase I Trial of COM701 in Advanced Solid Tumors

In an interview with CancerNetwork®, Henry Adewoye, MD, chief medical officer at Compugen, discussed the study of COM701, which was presented at the American Association for…

READ MORE

Valneva banks $130M as Pfizer buys into Lyme disease vaccine program

Shares in Valneva SE rose by as much as 32% during early trading April 30 on news that Pfizer Inc. is paying $130 million up front to in-license its…

READ MORE

Clinical Improvement Observed in Narcolepsy Trial Evaluating Once-Nightly Sodium Oxybate Formulation

Positive topline data from the phase 3 REST-ON trial evaluating FT218 (Avadel), an investigational, once-nightly formulation of sodium oxybate, showed that the treatment led to…

READ MORE

Biopharmas work to wallop COVID-19 respiratory effects, keeping patients off ventilators

Another company focused on severe respiratory complications of COVID-19 is La Jolla, Calif.-based Calcimedica Inc., which started a phase IIa study with its small-molecule calcium release-activated…

READ MORE

Rockefeller University, Cerevance Pursue Pooled Nuclei Sequencing to Target Brain Cell Types

A cell-targeting sequencing method developed at Rockefeller University is being used to find drug targets for neurological conditions such as Parkinson’s and Alzheimer’s diseases. Nuclear…

READ MORE

New type of checkpoint inhibitor offers early promise against tumors, but will it last?

A new type of checkpoint inhibitor from an Israeli biotech company called Compugen is showing early signs of halting tumor growth in patients with advanced…

READ MORE

Biotech Stock Hits Fresh High As It Plans To Launch A Drug Amid Virus

Immunomedics (IMMU) isn’t concerned the coronavirus pandemic could slow its launch of a new breast cancer treatment, an executive said Thursday, as IMMU stock rocketed on…

READ MORE

Developing immunotherapies for hard-to-treat cancers

Despite oncology being a focus of pharmaceutical R&D for decades, some cancers remain difficult to treat. Drug Target Review’s Hannah Balfour spoke with Hans Klingemann, MD, PhD,…

READ MORE

Cue Biopharma Pairs its Lead Candidate with Keytruda in Head and Neck Cancer Study

Cue Biopharma forged a clinical collaboration with Merck to combine its lead candidate CUE-101 with Merck‘s Keytruda as a first-line treatment for HPV+ recurrent/metastatic head and neck cancer.

READ MORE

Searching for a Covid Treatment

For high-risk seniors changing how they connect is a must during Coronavirus, and searching for a treatment.

View clip

Scynexis’ new antifungal on track for 2020 filing with phase 3 win

After outshining the standard of care for yeast infections in a midstage trial, Scynexis’ broad-spectrum antifungal has delivered again. The drug beat placebo at clearing…

READ MORE

Breakthrough in neurodegeneration: GV, Bill Gates and Foresight invest $45m in Cerevance

GV, Bill Gates and Foresight Capital joined three existing investors in Cerevance’s recent Series B round, which closed with $45m raised. The ability of this…

READ MORE

Morning Trade Live

How Redhill Biopharma is fighting COVID-19

View clip

“Who Are They?” A Biotech CEO’s Timeless Question For CDMOs

The question James E. Brown, President & CEO, DURECT asked of CDMOs when he founded the company in 1998 remains perfectly operational. “‘Who are they?’ is…

READ MORE

San Diego biotech company launches trials of drug to treat COVID-19 pneumonia

San Diego biotech company CalciMedica has partnered with two Midwestern hospitals to test a drug designed to help COVID-19 patients who are battling severe pneumonia.

READ MORE

Cerevance Banks $45 Million for Neurological Drug Development

Biotechnology startup Cerevance Inc. has secured $45 million to hunt for treatments for neurological diseases by studying samples of brain tissue gathered from deceased donors…

READ MORE

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About

At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying the right antibodies from recovered COVID-19 patients and…

READ MORE

Gates, GV chip into $45M round for CNS biotech Cerevance

Four months after inking its first Big Pharma partnership, Cerevance is topping up its coffers with a $45 million raise. The proceeds will push the company’s…

READ MORE

Coronavirus Survivors Needed: New Orleans Doctor is collecting blood samples from survivors to make treatment.

Research is critical during this pandemic. With so much unknown about the coronavirus, doctors and scientists are exploring new methods to finding a treatment. A…

READ MORE

Coronavirus In Minnesota: HealthPartners Begins Clinical Trial For Drug To Treat COVID-19 Pneumonia Patients

HealthPartners is now testing a drug which could treat severe COVID-19 pneumonia patients. The drug – called CM4620-IE – received fast-track approval from the FDA…

READ MORE

A new generation of antibody-drug conjugates for cancer patients

Scientists at Immunomedics have similarly loaded their ADC IMMU-132 (sacituzumab govitecan) with about eight SN-38 molecules in hopes of killing tumor cells via the bystander…

READ MORE

CalciMedica moves inflammation-targeting COVID-19 drug into phase 2

As the number of COVID-19 cases rises, so does the demand for critical medical supplies, leading governments and companies to ramp up the production of…

READ MORE

Refreshing how we approach neuroscience with a novel screening technology

“We need to have a more innovative approach to neuroscience; the pharmaceutical industry has been fixated too long on a handful of targets for serious…

READ MORE

‘A form of a robotic microscope’: Idaho physician uses exoscope to perform surgeries on patients

By the time Paul Huling needed surgery last fall, he couldn’t use his left arm. Huling first noticed a problem a few weeks before when…

READ MORE

A ‘shock and kill’ approach

Soon-Shiong explained that N-803 had also proven effective in a first-in-human immunotherapy clinical trial combining an IL-15 superagonist with NantKwest’s off-the-shelf, PD-L1 tumor-targeted NK cells (NCT04050709) in…

READ MORE